How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

998 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

products will be allowed (e.g., hair gel, mousse, styling spray). Willing to use a mild non-medicated shampoo and conditioner for the duration of the study Willing to receive a small scalp tattoo Able to read and understand English Exclusion Criteria: Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia Scalp hair loss on the treatment area, due to disease, injury, or medical therapy Males who are sexually active and have a partner who is capable of becoming pregnant, neither (...) , might put the subject at risk or interfere with the study conduct or evaluations History of surgical correction of hair loss on the scalp Previous exposure to SM04554 Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 24 weeks prior to study start Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start History of hair transplants Current use of an occlusive

2014 Clinical Trials

142. Minoxidil Response Testing in Males With Androgenetic Alopecia

.: alopecia androgenetic alopecia hair loss minoxidil 5% minoxidil foam male pattern hair loss Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Minoxidil Antihypertensive Agents Vasodilator Agents (...) : 18 Years to 49 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Males with androgenetic alopecia Criteria Inclusion Criteria: Males in overall good health Age: 18 to 49 Diagnosed with male androgenetic alopecia with vertex pattern IIIv, IV, or V on the Norwood Hamilton Scale Willing to have a mini dot tattoo placed in the target area of the scalp Willing to maintain the same hair style, color, shampoo and hair

2014 Clinical Trials

143. A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Andrasfay Therapeutics, Inc. More Information Go to Layout table for additonal information Responsible Party: Intrepid Therapeutics, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: 171-7152-201 First Posted: October 31, 2014 Last Update Posted: March 13, 2017 Last Verified: March 2017 Keywords provided by Intrepid Therapeutics, Inc.: androgen alopecia CB-03-01 solution topical Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases (...) information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 50 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subject has mild to moderate androgenetic alopecia (AGA) in temple and vertex region Subject is willing to maintain the same hairstyle, hair length, and hair color throughout the study Subject agrees to continue his other general hair care products and regimen for the entire study Subjects who are sexually

2014 Clinical Trials

144. Insulin-Like Growth Factor -1: Roles In Androgenetic Alopecia. (Abstract)

Insulin-Like Growth Factor -1: Roles In Androgenetic Alopecia. Of all the cytokines or growth factors that have been postulated to play a role in hair follicle, insulin-like growth factor-1 (IGF-1) is known to be regulated by androgens. However, how IGF-1 is altered in the balding scalp has not yet been investigated. In this study, expressions of IGF-1 and its binding proteins by dermal papilla (DP) cells obtained from balding versus non-balding hair follicles were quantified using growth (...) factor array. DP cells from balding scalp follicles were found to secrete significantly less IGF-1, IGFBP-2 and IGFBP-4 (P < 0.05) than their non-balding counterparts. Our data confirmed that the downregulation of IGF-1 may be one of the important mechanisms contributing to male pattern baldness.© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

2014 Experimental Dermatology

145. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. (Abstract)

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment.We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha (...) reductase inhibitor) and placebo in men with androgenetic alopecia.Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes.In total, 917 men were randomized. Hair count

2014 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

146. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. (Abstract)

Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. Hair loss may significantly impact an individual's self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL.The aim of this study was to assess QoL in patients (n (...)  = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist.Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16.Overall, patients rated their hair loss as more severe than the dermatologist, and the patient's HLS rating more strongly correlated with QoL than the dermatologist's rating. Clinical assessment of HLS did

2011 Journal of American Academy of Dermatology

147. Traction Alopecia (Diagnosis)

loss of follicular ostia, or atrophy. Clinical inflammation is frequently, but not always, present. Histologic inflammation may be present. Ultimately, histologic confirmation is the best method to confirm the presence of a fibrosing/scarring process with loss of hair follicles. Many alopecia types are biphasic. For example, androgenetic alopecia eventually results in loss of ostia and thus may appear like a scarring alopecia. This article focuses on the alopecia types that are believed to be due (...) be permanently destroyed. Note the image below. Alopecia due to primary cutaneous follicular center cell lymphoma. Used with permission, rights retained, courtesy of Rashid M. Rashid, MD, PhD, Morzak Research Collaborative. Alopecia mucinosa Follicular mucinosis can exist by itself or can be a manifestation of mycosis fungoides. Keratosis pilaris atrophicans Keratosis pilaris atrophicans involves a spectrum of conditions that resemble keratosis pilaris, but result in hair loss. Diagnoses in which neutrophils

2014 eMedicine.com

148. Androgenetic Alopecia (Treatment)

. The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. J Drugs Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya (...) . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants

2014 eMedicine.com

149. Traction Alopecia (Treatment)

and chemical hair straightening Use of tight curlers and nylon brushes Wearing the hair in a chignon (bun) Previous References Chiu HY, Lin SJ. Fibrosing alopecia in a pattern distribution. J Eur Acad Dermatol Venereol . 2010 Feb 2. . Olsen EA. Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. J Investig Dermatol Symp Proc . 2005 Dec. 10(3):217-21. . Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol . 2005 Jul. 53(1):1 (...) . Break dancing: a new risk factor for scarring hair loss. J Cutan Med Surg . 2011 May-Jun. 15(3):177-9. . Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol . 2001 Mar-Apr. 19(2):211-25. . Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Determinants of marginal traction alopecia in African girls and women. J Am Acad Dermatol . 2008 Sep. 59(3):432-8. . Ochoa BE, King LE Jr, Price VH. Lichen planopilaris: Annual incidence in four hair referral centers in the United

2014 eMedicine.com

150. Traction Alopecia (Overview)

loss of follicular ostia, or atrophy. Clinical inflammation is frequently, but not always, present. Histologic inflammation may be present. Ultimately, histologic confirmation is the best method to confirm the presence of a fibrosing/scarring process with loss of hair follicles. Many alopecia types are biphasic. For example, androgenetic alopecia eventually results in loss of ostia and thus may appear like a scarring alopecia. This article focuses on the alopecia types that are believed to be due (...) be permanently destroyed. Note the image below. Alopecia due to primary cutaneous follicular center cell lymphoma. Used with permission, rights retained, courtesy of Rashid M. Rashid, MD, PhD, Morzak Research Collaborative. Alopecia mucinosa Follicular mucinosis can exist by itself or can be a manifestation of mycosis fungoides. Keratosis pilaris atrophicans Keratosis pilaris atrophicans involves a spectrum of conditions that resemble keratosis pilaris, but result in hair loss. Diagnoses in which neutrophils

2014 eMedicine.com

151. Androgenetic Alopecia (Overview)

Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya Erdogan H, Bulur I, Kocaturk E, Yildiz B, Saracoglu ZN, Alatas O. The role of oxidative (...) in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants from balding and hairy androgenetic alopecia scalp regrow hair comparably well

2014 eMedicine.com

152. Traction Alopecia (Follow-up)

and chemical hair straightening Use of tight curlers and nylon brushes Wearing the hair in a chignon (bun) Previous References Chiu HY, Lin SJ. Fibrosing alopecia in a pattern distribution. J Eur Acad Dermatol Venereol . 2010 Feb 2. . Olsen EA. Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. J Investig Dermatol Symp Proc . 2005 Dec. 10(3):217-21. . Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol . 2005 Jul. 53(1):1 (...) . Break dancing: a new risk factor for scarring hair loss. J Cutan Med Surg . 2011 May-Jun. 15(3):177-9. . Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol . 2001 Mar-Apr. 19(2):211-25. . Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Determinants of marginal traction alopecia in African girls and women. J Am Acad Dermatol . 2008 Sep. 59(3):432-8. . Ochoa BE, King LE Jr, Price VH. Lichen planopilaris: Annual incidence in four hair referral centers in the United

2014 eMedicine.com

153. Androgenetic Alopecia (Follow-up)

. The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. J Drugs Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya (...) . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants

2014 eMedicine.com

154. Androgenetic Alopecia (Diagnosis)

Dermatol . 2011 Dec. 10(12):1404-11. . Brockschmidt FF, Heilmann S, Ellis JA, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br J Dermatol . 2011 Dec. 165(6):1293-302. . Kure K, Isago T, Hirayama T. Changes in the sebaceous gland in patients with male pattern hair loss (androgenic alopecia). J Cosmet Dermatol . 2015 Sep. 14 (3):178-84. . Kaya Erdogan H, Bulur I, Kocaturk E, Yildiz B, Saracoglu ZN, Alatas O. The role of oxidative (...) in the female sex. Br J Dermatol . 1977 Sep. 97(3):247-54. . Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet . 2008 Mar. 82(3):737-43. . . Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes . 2009 Jun. 16(3):246-53. . Krajcik RA, Vogelman JH, Malloy VL, Orentreich N. Transplants from balding and hairy androgenetic alopecia scalp regrow hair comparably well

2014 eMedicine.com

155. Clinical efficacy of a cosmetic treatment by Crescina(®) human follicle stem cell on healthy males with androgenetic alopecia. Full Text available with Trip Pro

Clinical efficacy of a cosmetic treatment by Crescina(®) human follicle stem cell on healthy males with androgenetic alopecia. Androgenetic alopecia (AGA) is the most common cause of hair loss among males, characterized by progressive thinning of the scalp hairs and defined by various patterns. The main factors underling hair loss in AGA are genetic predisposition and increased sensitivity of the hair follicles to androgens, leading to a shortening of the anagen phase. In the present study (...) , the authors investigated the efficacy of a commercially available cosmetic lotion, Crescina(®) HFSC (human follicle stem cell; Labo Cosprophar AG, Basel, Switzerland), in promoting hair growth and in decreasing hair loss.A placebo-controlled, randomized trial was carried out on healthy males suffering from alopecia grade II to IV. Anagen rate and hair resistance to traction (pull test) were assessed after 2 and 4 months of treatment using phototricogram and pull test technique.Crescina(®) HFSC applied

2013 Dermatology and therapy Controlled trial quality: uncertain

156. Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

25, 2013 Last Update Posted : June 25, 2013 Sponsor: Biotechnology Institute IMASD Information provided by (Responsible Party): Biotechnology Institute IMASD Study Details Study Description Go to Brief Summary: Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. This clinical trial was designed to evaluate the efficacy and safety of using a preparation (...) inflammation or infection in the intervention area Presence of active systemic infections. Background of cancerous or precancerous lesions. Background of connective or rheumatic diseases. Suffering from any serious blood disorders. To have undergone treatments for alopecia in the previous 6 months. Previous hair implants Intake of drugs that affect hair loss. Be undergoing immunosuppressive therapy and/or anticoagulants. Known intolerance to mesotherapy. Taking contraceptives containing cyproterone acetate

2013 Clinical Trials

157. A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia

a global photograph from an earlier assessment (i.e., a withdrawal visit), then that photograph was assessed during the panel review. Number of Participants With the Indicated Change From Baseline (BL) in the Stage of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at 26 Weeks and 52 Weeks [ Time Frame: Baseline, Week 26 and Week 52 ] The investigator/designee assessed the stage (Stage I to Stage VII) of AGA (i.e., male pattern baldness [MPB]) by utilizing the Norwood-Hamilton scale (...) , used to measure the progression of MPB. Stage VII indicates worse balding than Stage I. Assessment was made by direct visual examination (aided by pictures) of the participant at Screening (Baseline), Week 26, and Week 52. "v," vertex; most of the hair loss (commonly seen with advancing age) is on the vertex. "a," type a variant; major features are (1) the entire anterior hairline border recedes in unison; (2) there is no simultaneous balding of the vertex. The number of participants with stage

2013 Clinical Trials

158. Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia

National University Yangsan Hospital Study Details Study Description Go to Brief Summary: Androgenic alopecia is the most common cause of hair loss in men. Finasteride and minoxidil are available in treatment of androgenetic alopecia, although the former causes decreased libido or ejaculate volume, erectile dysfunction, the latter causes scaling, itching of the scalp. Recently, Pulpkin Seed Oil shows some improved clinical efficacy on scalp hair growth in men with androgenetic alopecia (...) Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect

2013 Clinical Trials

159. Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia

: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline ( Stiefel, a GSK Company ) Study Details Study Description Go to Brief Summary: Treatment of male pattern hair loss (MPHL) or androgenetic alopecia (AGA) with 5α-reductase inhibitor (5-ARIs) has been associated with sexual dysfunction including erectile dysfunction and loss of libido. This will be a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the impact of dutasteride treatment on sexual (...) consent, or compliance with study procedures.Note: the investigator may consult with the GSK medical monitor if a condition could interfere with the subject's safety. Global scalp hair thinning, including occipital areas. Scarring of the scalp, including prior hair transplant or scalp reduction, or any other condition or disease of the scalp or hair, including diseases of the hair shaft (e.g., tinea infection, non-androgenetic-cause of alopecia, psoriatic dermatitis or other psoriatic lesions

2013 Clinical Trials

160. Androgenetic Alopecia: Identification of Four Genetic Risk Loci and Evidence for the Contribution of WNT Signaling to Its Etiology. Full Text available with Trip Pro

Androgenetic Alopecia: Identification of Four Genetic Risk Loci and Evidence for the Contribution of WNT Signaling to Its Etiology. The pathogenesis of androgenetic alopecia (AGA, male-pattern baldness) is driven by androgens, and genetic predisposition is the major prerequisite. Candidate gene and genome-wide association studies have reported that single-nucleotide polymorphisms (SNPs) at eight different genomic loci are associated with AGA development. However, a significant fraction (...) descent to confirm the association with AGA at these loci. Combined analysis of the replication and the meta-analysis data identified four genome-wide significant risk loci for AGA on chromosomes 2q35, 3q25.1, 5q33.3, and 12p12.1. The strongest association signal was obtained for rs7349332 (P=3.55 × 10(-15)) on chr2q35, which is located intronically in WNT10A. Expression studies in human hair follicle tissue suggest that WNT10A has a functional role in AGA etiology. Thus, our study provides genetic

2013 Journal of Investigative Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>